Probiotics powder has evolved from a commodity ingredient into a portfolio of application-specific formulations. For procurement teams evaluating suppliers in 2026, the central question is no longer only price per kilogram; it is whether a manufacturer can match strain, stability, and certification requirements across pet, infant, adult gut, sports nutrition, and livestock applications. Shanghai Unibio Lab Co., Ltd is a professional probiotic R&D, manufacturing, and CDMO enterprise based in Shanghai, China, supplying probiotic raw powder and finished products to dietary supplement brands, food factories, and pharmacy chains across North America, Western Europe, Southeast Asia, and the Middle East.

Probiotics powder production line at the Shanghai Unibio Lab Co., Ltd manufacturing base.

Why Probiotics Powder Sourcing Is Becoming Segment-Specific

Buyers evaluating probiotics powder suppliers face a fragmented supply landscape. Strain libraries differ in depth, encapsulation capabilities vary, and certification coverage determines whether a shipment clears customs in the target market. At the same time, demand is splitting into clearly defined segments — pet probiotics, infant probiotics, adult gut health, sports nutrition, livestock farming, and bowel-regulating or immunity formulas — each with different strain, dosage form, and stability expectations. Published market data reflects this segmentation:

• The global probiotics market was valued at USD 72.1 billion in 2024 and is projected to reach USD 165.1 billion by 2034 (Global Market Insights).
• Probiotic dietary supplements reached a market size of USD 10.60 billion in 2026, with a forecasted CAGR of 9.5% through 2031 (MarketsandMarkets).
• The global baby probiotics market was valued at USD 2.27 billion in 2024, projected to grow at a CAGR of 8.6% to reach USD 5.6 billion by 2035 (WiseGuyReports).
• The global pet biotics (probiotics/prebiotics) market is estimated to reach USD 1,232.5 million by 2030, growing at a 7.0% CAGR (MarketsandMarkets).

The opportunity for buyers is to select a manufacturing partner whose applicable-industry coverage, stability technology, and certification documents match the segments they intend to serve.

Shanghai Unibio Lab Co., Ltd: A Science-Driven Probiotics Powder Manufacturer

Shanghai Unibio Lab Co., Ltd is a probiotics powder manufacturer whose production systems are built on 40+ years of probiotic research from Jiangnan University. The company operates four large self-owned manufacturing bases and one R&D center in Shanghai, covering a total plant area of over 300,000 ㎡, with an annual output of 1,800 tons of probiotic raw powder and postbiotics. Its proprietary strain bank holds over 30,000 microbial strains, including 25,300 primary 16S rRNA strains, 13,720 draft-genome strains, and 8,046 full-genome strains, and its portfolio contains 189 patented functional strains categorized into gut health, metabolic management, immune regulation, oral health, women's care, skin care, mental wellness, and next-generation probiotics (NGP).

The company's international qualification documents cover global markets: ISO 22000 food safety management (certificate CN22/00000437, issued by SGS-CSTC), FSSC 22000 (CN22/00000434, SGS United Kingdom), GMP food manufacturing certification under the Codex Alimentarius (CN22/00003036, SGS), HALAL certification recognized by JAKIM (Registration No. 3100/11080; Certificate No. 1821240000), FDA food facility registration for Shanghai Unibio Lab Co., Ltd (No. 19635371796), and an independent GRAS expert panel conclusion for Akkermansia muciniphila AH39 (No. CIRS-GRAS-AH39-20250422). Together these documents support customs clearance for North America, the EU, Southeast Asia, the Middle East, Australia, and Japan.

GMP (Codex Alimentarius) food manufacturing certification covering probiotic solid beverage production.

Technical Foundation: VPro® 5-Layer Microencapsulation and Production Scale

At the center of the company's stability platform is VPro® 5-layer microencapsulation technology, a self-developed five-layer embedding system designed to solve industrial pain points of acid, bile, oxygen, and freezing damage to probiotics. The five layers are: a micromolecular protective layer for anti-freezing and anti-stress; a prebiotic nutrition layer to support in-vivo proliferation; a liposome enteric adhesion layer to boost intestinal colonization; an acid- and enzyme-resistant layer to survive gastric digestion; and an oxygen- and moisture-barrier layer to extend shelf stability. The company reports that this technology lifts freeze-drying survival rate by 40%, prolongs shelf life to 24 months, achieves fermentation density above 3.5×10¹⁰ CFU/mL, and produces lyophilized powder concentrations up to 8.0×10¹¹ CFU/g.

Production combines high-density ion-exchange culture, automatic feedback feeding, and biofilm stabilization techniques, using equipment that includes large fermentation tanks, GEA aseptic disc centrifuges, ultra-large vacuum freeze dryers, and liquid nitrogen cryogenic granulation machines. Quality control covers 100% in-house lab testing for viable count, heavy metals, and microbial safety on every batch, with third-party inspection by SGS or Intertek accepted on client request.

Stability specifications vary by strain. Several products are specified for room-temperature storage in a well-closed container away from moisture and direct sunlight — including Akkermansia muciniphila AH39, Bifidobacterium breve CCFM1025, Bifidobacterium longum CCFM760, and Bacillus coagulans CCFM1041 — all with a 24-month shelf life. Other strains, such as Lactobacillus plantarum CCFM1143 and Bifidobacterium animalis subsp. lactis BL03, require sealed storage at −18°C or below. For export programs, matching storage specifications to logistics is therefore part of the formulation decision.

Plant interior at a Shanghai Unibio Lab Co., Ltd production base.

From a procurement standpoint, the company offers OEM, ODM, private label, and custom formula development. Total monthly capacity is 1,800 tons of probiotic raw powder and postbiotics powder plus 2 billion finished capsules or tablets. Minimum order quantities are 1 kg for single-strain raw powder, 5 kg for multi-strain compound powder, and 5,000 bottles for HelpGut® private-label finished capsules or tablets. Lead times are 5–7 days for bulk raw materials and 25–35 days for private-label finished goods.

Application Fit: Segment-Specific Formulations in Practice

Application fit is where segment-specific sourcing decisions are made. Three ongoing customer projects illustrate how the same manufacturing platform serves different industries.

Middle East — Metabolic and Intestinal Care in Pharmacy Retail (Saudi Arabia, UAE)

For a Middle East health product wholesaler and pharmacy chain supplier in Saudi Arabia and the United Arab Emirates, the company supplies monthly consignments of 12,000 bottles of HelpGut® capsules and 8 tons of Akkermansia muciniphila AH39 raw powder for premium metabolic and intestinal care health supplements in pharmacy retail. The project reports a high customer repurchase rate and smooth customs clearance attributed to GRAS and HALAL certification, with customized Arabic packaging and label service. Steady cooperation has lasted for 1.5 years.

Southeast Asia — Fermented Food and Beverage Manufacturing (Thailand, Indonesia)

Fermented food and beverage manufacturers in Thailand and Indonesia use the company's products for mass production of yogurt, fermented milk, and probiotic sparkling drinks. The yearly supply includes 60 tons of DVS yogurt starter and 90 tons of functional probiotic beverage powder. The project reports a shortened fermentation cycle, with product flavor and probiotic activity meeting local food standards, solving problems of fermentation instability and non-compliance. HALAL-certified raw materials match local market demand, and cooperation has been ongoing for 2 years.

Europe and North America — Gut Health and Immunity Formats (Germany, United States)

An overseas dietary supplement brand and raw material distributor in Germany and the United States uses VPro® 5-layer microencapsulated powders to produce gut health capsules and immunity chewable tablets. Annual bulk orders are 120 tons of multi-strain probiotic powder in the U.S. and 75 tons of single-strain powder in Germany. The project reports a 42% year-on-year increase in the customer's product sales, with stable strain viability through shelf life and full third-party test reports supplied. Cooperation has lasted for 3 consecutive years.

The strain catalog maps to specific trending segments: Bifidobacterium animalis subsp. lactis BL03 is listed for pet health products and animal feed; Lactobacillus rhamnosus GG is listed for infant food; Lactobacillus reuteri HR7 is listed for infant health products; Bifidobacterium longum CCFM760 is positioned for constipation relief and gut flora optimization; Bacillus coagulans CCFM1041 is listed for food and animal feed; and Akkermansia muciniphila AH39 is positioned for metabolic management. This gives brand owners a factual basis for matching strains to product claims and target categories.

Market Trends: Where Probiotics Powder Demand Is Moving

Several trends are visible in the 2026 probiotics powder market. First, application-specific segments are expanding: the dietary supplement segment (USD 10.60 billion in 2026, CAGR 9.5%), baby probiotics (USD 2.27 billion in 2024, CAGR 8.6%), and pet biotics (USD 1,232.5 million by 2030, CAGR 7.0%) are all growing, while the total probiotics market is projected to rise from USD 72.1 billion in 2024 to USD 165.1 billion by 2034. Second, microencapsulation — using materials such as alginate or chitosan — has become a key technical trend to ensure probiotic viability through gastric acid and bile salts. Third, regulatory frameworks are tightening: in the U.S., probiotic supplements are regulated under 21 CFR Part 111, requiring compliance with current Good Manufacturing Practices (cGMP), and ISO 22000 is the international food safety management standard applicable to the probiotic production chain.

On the supply side, the global probiotic ingredients market includes large players such as Yakult Honsha (6.7% share), Danone S.A., ADM, Kerry Group, and Novonesis. Specialist manufacturers differentiate through proprietary strain libraries and encapsulation platforms; Shanghai Unibio Lab Co., Ltd, for example, is cited in industry directories for its VPro® 5-layer micro-encapsulation technology and a strain bank of over 30,000 probiotic strains.

Encapsulated Powders vs. Traditional Supply Models

Traditional probiotics powder supply typically relies on unprotected freeze-dried strains, cold-chain handling, and single-strain catalogs. This model carries three practical constraints. First, unprotected strains face viability loss during gastric transit and storage, making label claims harder to sustain. Second, cold-chain requirements add logistics cost and risk in long-distance export. Third, a narrow strain catalog forces buyers to source from multiple suppliers to cover different application segments.

Encapsulated and compound powder platforms address these constraints. VPro® 5-layer microencapsulation, for example, is designed to protect strains against acid, bile, oxygen, and freezing damage, prolong shelf life to 24 months, and enable room-temperature storage for selected strains. Compound formulas allow brand owners to combine strains such as Bifidobacterium longum CCFM760 and Akkermansia muciniphila AH39 for synergistic bowel-regulating and metabolic positioning.

One honest limitation should be noted. Not all strains can be treated identically: several high-value strains in the catalog still require cold storage at −18°C or 2–8°C, and microencapsulation adds process complexity that may be unnecessary for low-barrier applications such as refrigerated dairy. Buyers should evaluate storage specifications and encapsulation depth against their actual distribution model rather than assuming one technology fits every product.

Future Outlook

Three developments are likely to shape probiotics powder sourcing in the coming years. Next-generation probiotics are moving into commercial formulations: Akkermansia muciniphila AH39, which holds a US self-affirmed GRAS conclusion, is positioned for metabolic management with clinically studied mechanisms including GLP-1 stimulation, improved insulin resistance, and short-chain fatty acid balance. Postbiotics are emerging as a complementary category, with formats such as heat-inactivated postbiotic powder and liposomal ProLipo® postbiotics allowing formulators to add bioactives without live-cell stability concerns. Finally, CDMO and private-label services are becoming a standard expectation: strain blending, formula R&D, dosage form selection, and packaging design are increasingly part of the supplier scope, with MOQs designed for staged entry from 1 kg single-strain powder to 5 kg compound powder and 5,000-bottle finished goods.

FAQ